Sleep claims and evidence

Medicinal cannabis is one of the most common reasons people ask about prescription cannabinoids in New Zealand. The evidence, however, is more limited than marketing suggests. Current research shows a small, short-term improvement in sleep quality when sleep disturbance is tied to chronic pain. The effect is modest, secondary to pain relief, and not well studied as a standalone insomnia treatment. Long-term data are missing. This article explains what the research actually shows, the difference between short-term and long-term effects, and the practical limits of the evidence, so you can have a realistic conversation with your prescriber.

What the evidence says about sleep

Systematic reviews of randomised controlled trials have examined cannabis for sleep. The results are not as strong as many patients hope. A 2022 systematic review in the BMJ found that cannabinoids were associated with a small improvement in sleep quality in people with chronic pain. The effect was modest and secondary to pain relief rather than a direct sedative action. The same review noted that most trials were short, lasting 2 to 8 weeks, and that long-term data were missing.

The New Zealand Formulary and the New Zealand Ministry of Health do not list sleep as a primary indication for medicinal cannabis. The NZ Formulary (2024) notes that evidence for insomnia is limited. Any sleep benefit is reported as an improvement in sleep disturbance linked to an underlying condition, not as a standalone sleep medicine. Healthify (New Zealand’s public health information service) states that while some people report better sleep with medicinal cannabis, the quality of evidence is low and effects vary.

Short-term findings

• A 2023 systematic review of cannabinoids for chronic pain (published in the BMJ) found that patients reported a small improvement in sleep quality as a secondary outcome when pain was reduced. The review authors rated the certainty of this evidence as low to moderate.
• A 2022 review by the New Zealand Ministry of Health noted that evidence for sleep as a primary indication is “limited.” Most supporting data come from studies of chronic pain, multiple sclerosis, or cancer-related symptoms, not from insomnia trials.
• Short-term use of THC-dominant products is associated with faster sleep onset in some studies. The effect is not sustained beyond a few weeks.

How cannabis affects sleep architecture

Cannabis alters the normal stages of sleep. The two main cannabinoids, THC and CBD, have different and sometimes opposing effects. Understanding these differences helps explain why short-term relief does not always translate into restorative long-term sleep.

THC

THC is the main psychoactive component of cannabis. It binds to CB1 receptors in the brain and central nervous system. In the short term, THC can reduce the time it takes to fall asleep. It also increases slow-wave sleep, the deep sleep stage important for physical restoration.

The trade-off is that THC suppresses REM sleep, the stage associated with dreaming, emotional processing, and memory consolidation. Reduced REM sleep can leave some people feeling groggy or cognitively dull the next day. With regular use, tolerance to the sleep-promoting effects of THC develops quickly. Users may need higher doses to achieve the same sedation, which can worsen next-day impairment and increase the risk of dependence.

When THC is stopped after regular use, REM sleep rebounds. This rebound can cause vivid dreams, nightmares, and disrupted sleep, which makes it harder to stop using the product even when it is no longer helping.

CBD

CBD is non-intoxicating and does not bind directly to CB1 receptors in the same way as THC. Its effects on sleep are less direct and appear to be dose-dependent. At lower doses, CBD may promote wakefulness. At higher doses, some studies suggest a sedating effect, though the evidence is inconsistent.

CBD does not suppress REM sleep in the way THC does. For some people, this means CBD is less likely to cause next-day grogginess or REM rebound on stopping. The main sleep-related role for CBD in current New Zealand prescribing is for anxiety or pain that interferes with sleep, rather than as a direct sleep aid.

Long-term concerns and risks

The long-term effects of using cannabis for sleep are poorly understood. Most clinical trials last 2 to 8 weeks. Observational studies and withdrawal research point to several concerns that matter for anyone considering medicinal cannabis as a sleep treatment.

Tolerance and dose escalation

With nightly use, tolerance to the sedative effects of THC develops. A dose that initially helped with sleep onset may stop working. Increasing the dose can restore the short-term effect, but this also increases the risk of next-day impairment, dependence, and withdrawal symptoms on stopping.

Withdrawal and sleep disruption

Regular use of THC-dominant products can lead to physical dependence. When use is reduced or stopped, sleep disruption is one of the most common withrawal symptoms. People report difficulty falling asleep, frequent waking, and vivid, unpleasant dreams. This withdrawal insomnia can last for days to weeks and is a significant barrier to discontinuing a product that is no longer providing benefit.

Next-day impairment

THC can impair memory, attention, and psychomotor performance the day after use, even when the user feels subjectively normal. This residual impairment is relevant for driving, operating machinery, and making complex decisions. The New Zealand Ministry of Transport has a zero-tolerance approach to driving with impairing drugs. Medicinal cannabis patients must not drive if impaired and should discuss driving safety with their prescriber before starting any cannabinoid product.

Psychiatric risks

Regular use of high-THC products is associated with an increased risk of anxiety, depression, and, in susceptible individuals, psychosis. People with a personal or family history of psychosis or bipolar disorder should be particularly cautious. The New Zealand Formulary advises that caution is required in patients with a history of psychiatric illness.

Cardiovascular effects

THC increases heart rate and can cause a temporary rise in blood pressure. For most people this is not clinically significant. For people with pre-existing cardiovascular disease, the risk may be higher. The New Zealand Formulary lists caution in cardiovascular disease as a prescribing consideration.

What to discuss with your prescriber

If you are considering medicinal cannabis for sleep, a structured conversation with your prescriber is the most reliable way to weigh potential benefit against known risk. The questions below are designed to surface the information that matters most for an informed decision.

• What is the underlying cause of my sleep problem? Medicinal cannabis is most likely to help when sleep disturbance is secondary to a condition with some evidence of benefit, such as chronic pain or spasticity. If the primary problem is insomnia, the evidence for cannabis is weak.
• What is the THC:CBD ratio of the product being considered? THC-dominant products carry more risk of tolerance, dependence, next-day impairment, and withdrawal. CBD-dominant or balanced products have a different risk profile but less direct evidence for sleep.
• What is the planned duration of use? Short-term use (days to weeks) has a different risk-benefit balance than open-ended nightly use. Ask whether a stop date or review point is planned.
• How will we know if it is working? Agree on a measurable goal, such as a specific reduction in time to fall asleep or fewer nightly wakings, and a timeline for review.
• What are the risks for driving and work? Discuss New Zealand’s legal limits for driving with impairing drugs and whether your work requires you to operate machinery or make safety-critical decisions.
• What is my personal risk for psychiatric or cardiovascular side effects? Disclose any personal or family history of psychosis, bipolar disorder, or heart conditions.
• What happens if I want to stop? Ask about tapering plans and what to expect from withdrawal, particularly sleep disruption and vivid dreams.

Medicinal cannabis and sleep in New Zealand: the practical picture

Medicinal cannabis in New Zealand is available by prescription only. It is not a first-line treatment for sleep. The Medical Cannabis Scheme requires that a doctor assess whether the potential benefits outweigh the risks for the individual patient. For sleep, this usually means the doctor must be satisfied that standard treatments have been tried and were ineffective or caused unacceptable side effects.

The products available in New Zealand include oils, dried flower for vaporisation, and oral formulations. The choice of product, dose, and timing is individualised. There is no standard dose for sleep. Most prescribers start with a low dose and titrate slowly, monitoring for both benefit and side effects.

Cost is a practical consideration. Medicinal cannabis products are not subsidised in New Zealand. Patients pay the full cost of the consultation and the product. Prices vary by product and dose, but monthly costs can run to hundreds of dollars. This matters for the risk-benefit calculation because a treatment with modest evidence and known risks may still represent a significant financial commitment.

What the evidence leaves unanswered

The research on cannabis and sleep has real gaps that limit how confidently anyone can recommend it as a sleep treatment. The most important gaps are:

• Long-term efficacy. Almost no trial data exist beyond 8 weeks. Whether any sleep benefit is maintained, or whether tolerance erases it, is unknown for most people.
• Comparisons with established treatments. There are few head-to-head trials of cannabis against cognitive behavioural therapy for insomnia (CBT-I) or against standard sleep medications. Without these comparisons, it is hard to know where cannabis fits in the treatment sequence.
• Which product for which patient. The evidence does not allow confident matching of specific THC:CBD ratios, doses, or formulations to specific sleep complaints. Prescribing remains largely trial and error.
• Safety in older adults. Older adults are more likely to have sleep complaints and more vulnerable to next-day falls, cognitive impairment, and drug interactions. The evidence for safety and efficacy in this group is particularly thin.

These gaps do not mean cannabis is ineffective for sleep. They mean the decision to use it is made with more uncertainty than for treatments with a larger and longer evidence base. A prescriber who is honest about these gaps is not dismissing cannabis as an option. They are describing the evidence as it actually stands.